NCT06532812 - TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 22, 2024

Primary Completion Date

December 10, 2025

Study Completion Date

December 28, 2026

Conditions

Breast CancerBreast CarcinomaBreast Cancer MetastaticBreast Cancer Triple Negative

Interventions

BIOLOGICAL

Tumor Infiltrating Lymphocytes (TIL)

Tumor Infiltrating Lymphocytes (TIL) IV

DRUG

Cyclophosphamid

Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.

DRUG

Fludarabine

Fludarabine will be administered as an intravenous (IV) infusion for five days.

DRUG

Interleukin-2

After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.

DRUG

Pembrolizumab

Intravenous (IV) infusion

Trial Locations (1)

RECRUITING

District One Hospital, Beijing